Novartis says Kesimpta gets EU approval in multiple sclerosis

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company’s headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau

ZURICH (Reuters) – Novartis AG said on Tuesday Kesimpta (ofatumumab) has won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.

The Swiss drugmaker is developing and marketing the product under a license agreement with Genmab.

Source: Read Full Article

Related posts:
  1. Novartis joins CureVac's vaccine contractor line-up
  2. 59.3 million doses of COVID-19 vaccines distributed, 39 million administered: U.S. CDC
  3. South Africa to roll out AstraZeneca vaccine in steps to assess effectiveness
  4. Europe clears J&J's single-shot COVID-19 vaccine as roll-out falters